Ernexa Therapeutics Inc. Earnings Per Share (Basic)
Ernexa Therapeutics Inc. (ERNA) reported Earnings Per Share (Basic) of -$3.40 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Ernexa Therapeutics Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$3.40.
- Ernexa Therapeutics Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$6.95.
- Ernexa Therapeutics Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.18.
- Ernexa Therapeutics Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.15.
- Ernexa Therapeutics Inc. earnings per share, basic for fiscal 2025 was -$2.24.
- Ernexa Therapeutics Inc. earnings per share, basic for fiscal 2024 was -$48.96.
- Ernexa Therapeutics Inc. earnings per share, basic for fiscal 2023 was -$4.08.
- Ernexa Therapeutics Inc. earnings per share, basic for fiscal 2022 was -$8.06.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.40 10-Q · filed 2026-08-06 | -$9.63 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | -$6.95 10-Q · filed 2026-05-11 | |||||||
| 2025-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-03-13 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-03-13 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.24 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | -$0.15 10-Q · filed 2025-11-07 | -$1.04 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.23 10-Q · filed 2025-11-07 | |||||
| 2025-06-30 | -$15.19 10-Q · filed 2026-08-06 | -$0.61 10-Q · filed 2025-08-13 | -$65.22 10-Q · filed 2026-08-06 | -$2.61 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | -$57.76 10-Q · filed 2026-05-11 | -$0.15 10-Q · filed 2025-05-07 | ||||||
| 2024-12-31 | -$2.26 derived: net income ÷ weighted average shares · filed 2026-03-13 | -$22.19 derived: net income ÷ weighted average shares · filed 2026-03-13 | -$34.68 derived: net income ÷ weighted average shares · filed 2026-03-13 | -$48.96 10-K · filed 2026-03-13 | -$3.26 10-K · filed 2025-03-12 | |||
| 2024-09-30 | -$73.70 10-Q · filed 2025-11-07 | -$4.92 10-Q · filed 2024-11-12 | -$89.03 derived: net income ÷ weighted average shares · filed 2025-11-07 | -$107.45 10-Q · filed 2025-11-07 | -$7.17 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | -$15.34 10-Q · filed 2025-08-13 | -$1.02 10-Q · filed 2024-08-13 | -$33.75 10-Q · filed 2025-08-13 | -$2.25 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | -$1.23 10-Q · filed 2025-05-07 | |||||||
| 2023-12-31 | -$1.14 derived: net income ÷ weighted average shares · filed 2025-03-12 | -$2.17 derived: net income ÷ weighted average shares · filed 2025-03-12 | -$3.03 derived: net income ÷ weighted average shares · filed 2025-03-12 | -$4.08 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | -$1.03 10-Q · filed 2024-11-12 | -$1.89 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$2.94 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | -$0.85 10-Q · filed 2024-08-13 | -$1.90 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$1.06 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | -$1.24 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$3.59 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$4.80 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$8.06 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | -$2.49 10-Q · filed 2023-11-13 | -$3.65 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$7.04 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$1.16 10-Q · filed 2023-08-11 | -$0.06 10-Q · filed 2022-08-11 | -$4.55 10-Q · filed 2023-08-11 | -$0.23 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | -$3.50 10-Q · filed 2023-05-11 | -$0.17 10-Q · filed 2022-07-01 | ||||||
| 2021-12-31 | -$3.05 derived: net income ÷ weighted average shares · filed 2023-03-20 | -$36.60 derived: net income ÷ weighted average shares · filed 2023-03-20 | -$6.56 derived: net income ÷ weighted average shares · filed 2023-03-20 | -$56.61 10-K · filed 2023-03-20 | -$2.82 10-K · filed 2022-04-15 | |||
| 2021-09-30 | -$34.03 10-Q · filed 2022-11-14 | -$1.70 10-Q · filed 2021-11-12 | -$4.27 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$56.79 10-Q · filed 2022-11-14 | -$2.82 10-Q · filed 2021-11-12 | -$7.46 derived: net income ÷ weighted average shares · filed 2022-11-14 | ||
| 2021-06-30 | -$0.24 10-Q · filed 2022-08-11 | -$0.81 10-Q · filed 2022-08-11 | -$0.79 10-Q · filed 2021-08-13 | -$1.54 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$1.69 derived: net income ÷ weighted average shares · filed 2022-08-11 | |||
| 2021-03-31 | -$0.67 10-K/A · filed 2022-07-01 | -$0.64 10-Q · filed 2021-05-17 | -$2.35 derived: net income ÷ weighted average shares · filed 2022-07-01 | -$1.93 derived: net income ÷ weighted average shares · filed 2022-07-01 | -$1.88 derived: net income ÷ weighted average shares · filed 2022-07-01 | |||
| 2020-12-31 | -$0.13 derived: net income ÷ weighted average shares · filed 2022-07-01 | -$0.24 derived: net income ÷ weighted average shares · filed 2022-07-01 | -$0.36 derived: net income ÷ weighted average shares · filed 2022-07-01 | -$0.41 10-K/A · filed 2022-07-01 | -$1.51 10-K · filed 2022-04-15 | |||
| 2020-09-30 | -$0.11 10-Q · filed 2021-11-12 | -$0.23 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.29 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$0.12 10-Q · filed 2021-08-13 | -$0.17 10-Q · filed 2021-08-13 | ||||||
| 2020-03-31 | -$0.06 10-Q · filed 2021-05-17 | |||||||
| 2019-09-30 | -$0.12 derived: net income ÷ weighted average shares · filed 2020-11-13 | -$0.27 derived: net income ÷ weighted average shares · filed 2020-11-13 | ||||||
| 2018-09-30 | $0.08 10-Q · filed 2018-11-09 | -$0.12 10-Q · filed 2018-11-09 | ||||||
| 2017-09-30 | -$0.07 10-Q · filed 2018-11-09 | -$0.18 10-Q · filed 2018-11-09 | ||||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-14 | -$0.01 10-Q · filed 2013-11-14 | ||||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-14 | -$0.02 10-Q · filed 2013-11-14 | ||||||
| 2011-09-30 | -$0.01 10-Q · filed 2012-11-09 | -$0.04 10-Q · filed 2012-11-09 | ||||||
| 2010-09-30 | $0.00 10-Q · filed 2011-11-14 | -$0.01 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |